Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-030056
Filing Date
2025-02-28
Accepted
2025-02-28 16:27:22
Documents
111
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K fdmt-20241231.htm   iXBRL 10-K 3700731
2 EX-4.1 fdmt-ex4_1.htm EX-4.1 55206
3 EX-10.19 fdmt-ex10_19.htm EX-10.19 225435
4 EX-10.20 fdmt-ex10_20.htm EX-10.20 71454
5 EX-10.21 fdmt-ex10_21.htm EX-10.21 103959
6 EX-19.1 fdmt-ex19_1.htm EX-19.1 215572
7 EX-23.1 fdmt-ex23_1.htm EX-23.1 2374
8 EX-31.1 fdmt-ex31_1.htm EX-31.1 21703
9 EX-31.2 fdmt-ex31_2.htm EX-31.2 21609
10 EX-32.1 fdmt-ex32_1.htm EX-32.1 12980
11 GRAPHIC img229904167_0.gif GRAPHIC 40415
12 GRAPHIC img232458856_0.jpg GRAPHIC 38368
  Complete submission text file 0000950170-25-030056.txt   15203983

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fdmt-20241231.xsd EX-101.SCH 2035062
114 EXTRACTED XBRL INSTANCE DOCUMENT fdmt-20241231_htm.xml XML 2463324
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39782 | Film No.: 25690770
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)